Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$7.80
+$0.06 · +0.78%
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Previous close
$7.80
+$0.06 · +0.78%
After-hours
$7.80
$0.00 · 0.00%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Day range
Current $7.80
52-week range
Current $7.80
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
91
Deep Value
Sentiment
44
Mixed
Risk
59
Elevated Risk
Momentum
53
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Day range
Current $7.80
52-week range
Current $7.80
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 297.18M USD | 266.27M USD | 202.09M USD | 148.62M USD | 99.67M USD |
| Cost of goods sold | 104.41M USD | 83.97M USD | 61.56M USD | 58.84M USD | 43.53M USD |
| Gross profit | 192.76M USD | 182.3M USD | 140.53M USD | 89.77M USD | 56.14M USD |
| Research and development | 9.58M USD | 9.17M USD | 15.43M USD | 6.74M USD | 2.06M USD |
| Selling, general, and administrative | 220.79M USD | 198.03M USD | 164.94M USD | 141.84M USD | 112.07M USD |
| Operating expenses | 230.36M USD | 216.72M USD | 189.76M USD | 155.1M USD | 100.54M USD |
| Interest income | 1.93M USD | 3.26M USD | 860K USD | 119K USD | 1K USD |
| Interest expense | 19.69M USD | 18.74M USD | 13.83M USD | 9.1M USD | 1.4M USD |
| Depreciation and amortization | 8.74M USD | 6.02M USD | 5.87M USD | 4.5M USD | 6.31M USD |
| Operating income | −37.6M USD | −34.41M USD | −49.23M USD | −65.33M USD | −44.41M USD |
| Net income | −51.64M USD | −50.42M USD | −61.69M USD | −74.41M USD | −46.81M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$18.40
135.90% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI14.04M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM12.14M0.02%77.7B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF6.97M0.01%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO4.22M0.03%14.04B USD0.24%$353.47-0.53%
State Street SPDR S&P Pharmaceuticals ETFXPH3.33M0.72%453.39M USD0.35%$63.63+1.14%
Vanguard Russell 2000 ETFVTWO3.1M0.02%18B USD0.06%$112.1-0.10%
Schwab U.S. Small-Cap ETFSCHA2.38M0.01%21.7B USD0.03%$32.66+0.15%
iShares U.S. Pharmaceuticals ETFIHE1.57M0.10%1.53B USD0.37%$98.86-0.53%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Pharmaceuticals ETFIHEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
